The thought of starting a family at a fertility clinic shouldn't be a dream, it should be a tangeable reality.
Goodbye 30% fertility plateau.
Incintas is about to replace you with much better odds to achieve pregnancy in assisted reproduction.
IVF / IUI / Artificial Insemination / Timed Intercourse
INCINTAS THERAPEUTICS, INC.
Driving cutting edge technology by resolving what every other technology is trying to monitor: uterine receptivity.
Incintas refines the way we prepare the uterus by using extended release, targeted hormonal therapeutics.
What is Known:
It is imperative for the "Window of Implantation" to be open in order for pregnancy to be achieved both in healthy pregnancy and in Assisted Reproduction Technologies (ART) that include; IVF, IUI, artificial insemination and timed intercourse treatments. When this window is closed, pregnancy is impossible because the embryo cannot implant into the uterine lining.
Did you know?
The current Implantation Window in ART
is only "open" for 24 hours on average, compared to 6 days in healthy pregnancy? This fact is clinically validated and more importantly, the rate-limiting factor in achieving pregnancy.
THE SCIENCE BEHIND THE INNOVATION
When women undergo fertitlity treatment, it is necessary to administer progesterone (the pregnancy hormone) so that they become pregnant. They are given what is called "luteal phase support" which is either administered perivaginally, IM injection, oral, rectal or subcutaneous injection. These administrations allow progesterone to travel through the woman's bloodstream to achieve two important goals; 1. establish a receptive uterine lining so that an embryo can implant to acheive pregnancy and 2. maintain the pregnancy by preventing menses and loss of the pregnancy (which is luteal support).
The problem with these adminitrations is that they do the second task really well but not the first one (establishing receptivity). When progesterone is allowed to travel through the bloodstream it does not provide the proper concentration range within the uterine lining for more than about 24 hrs. This is a big problem because it restricts embryonic implantation for most embryos, which is the biggest hurdle in achiving pregnancy in assisted reproduction since the late 1970's.
Incintas Therapeutics has separated these two administrations into a novel targeted intratuerine/peri-uterine administration that is solely intended to prolong endometrial receptivity and allow an embryo more time to implant and achieve pregnancy. After pregnancy is achieved, conventional luteal phase support is administered. It does a great job at sustaining the pregnancy until the placenta synthesizes progesterone naturally around week 10-12.
This novel refined protocol, routes of administration and time-release capabilites are patent protected by Incintas Therapeutics, Inc. and in current development.
Unlike all other IVF products on the market,
Incintas' technology doesn't monitor embryonic receptivity,
it precisely modulates it by administering progesterone directly where implantation occurs.
About Us
WHAT WE DO
"We intend to move the needle pretty far in assisted reproduction by focusing upon failed implantation."
Incintas Therapeutics is comprised of an accomplished team of scientists, physicians, geneticists and business professionals who are focused upon improving pregnancy outcome in reproductive medicine.
Our sole purpose is to resolve the problem of failed embryonic implantation (the main hurdle in achieving pregnancy in IVF) to ultimately encourage Single Embryo Transfer (SET) which is more likely to result in a healthy singleton pregnancy for the infertile couple.
DISCOVERY
Endometrial Progesterone Concentration (not Serum).
Measuring serum progesterone is not a reliable means of determining uterine receptivity, (E. Labarta and B. Lawrenz)
Mitchell V. Pizolato,
Nov. 23 -Nov. 29, 2000.
Multiple IVF Birth
Lance D. Pizolato
Nov. 23 - Dec. 1, 2000
Multiple IVF Birth
Rest in Peace, my dear sons.
